Plasma immunoreactive endothelin-1 in experimental malignant hypertension

Area of Science:

• Cardiovascular Research
• Renal Physiology
• Endocrinology

Background:

• Endothelin-1 (ET-1) is a potent vasoconstrictor implicated in hypertension.
• The role of ET-1 in different models of malignant hypertension requires further elucidation.

Purpose of the Study:

• To investigate plasma immunoreactive endothelin-1 (irET-1) concentrations in rat models of prehypertension and malignant hypertension.
• To differentiate the contribution of elevated blood pressure versus the hypertensive condition itself to irET-1 levels.

Main Methods:

• Measurement of plasma irET-1 in spontaneously hypertensive rats (SHR) and Wistar-Kyoto (WKY) rats under normal and deoxycorticosterone acetate (DOCA)-salt induced hypertension.
• Assessment of irET-1 in two-kidney, one clip (2K1C) renovascular hypertensive rats with and without chronic caffeine administration.
• High-performance liquid chromatography (HPLC) to characterize irET-1 in plasma.

Main Results:

• Plasma irET-1 levels were not elevated in prehypertensive or young/mature SHR compared to WKY rats.
• DOCA-salt treatment significantly increased blood pressure, renal markers, and plasma irET-1 in SHR, but not WKY rats.
• Caffeine administration in 2K1C rats increased blood pressure, renal markers, and plasma irET-1, while sham-operated rats showed no changes.
• HPLC analysis confirmed the presence of synthetic ET-1 (1-21) in plasma extracts from rats with malignant hypertension.
• Acute hypertension induced by angiotensin II or phenylephrine did not alter plasma irET-1 concentrations.

Conclusions:

• Plasma ET-1 concentrations are elevated in rat models of malignant hypertension.
• The increase in plasma ET-1 during malignant hypertension is associated with the specific hypertensive condition, rather than solely being a consequence of elevated blood pressure.